Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Arcus Biosciences Inc (RCUS)  
$15.55 0.82 (5.57%) as of 4:30 Fri 4/26


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 64,920,000
Market Cap: 1.01(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $13.43 - $23.54
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    : 31.4
Insider 6 Months    : 31.4
Insider 3/6 Months : 63.1
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating cancer therapies. Co.'s products include: Domvanalimab, which is an anti-TIGIT monoclonal antibody designed to promote sustained immune activation and tumor clearance; Etrumadenant, which is a dual A2a/A2b adenosine receptor antagonist, designed to inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes and myeloid cells; AB680, which is a potent and selective small-molecule CD73 inhibitor designed to provide differential benefits relative to monoclonal antibodies; and Zimberelimab, which is Co.'s anti-PD-1 antibody that Co. in-licensed to enable the development of its combination regimens.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 15,238,095 15,238,095 16,248,095 16,248,095
Total Buy Value $319,999,995 $319,999,995 $339,452,595 $339,452,595
Total People Bought 1 1 1 1
Total Buy Transactions 1 1 2 2
Total Shares Sold 110,657 141,439 237,875 329,459
Total Sell Value $2,164,815 $2,731,452 $4,652,676 $7,003,905
Total People Sold 2 4 4 6
Total Sell Transactions 6 10 16 33
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 88
  Page 1 of 4  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Jarrett Jennifer Chief Operating Officer   •       –      –    2024-03-27 4 AS $17.55 $202,720 D/D (11,551) 215,253 -20%     
   Jarrett Jennifer Chief Operating Officer   •       –      –    2024-03-18 4 S $17.84 $240,941 D/D (13,449) 226,804 14%     
   Jarrett Jennifer Chief Operating Officer   •       –      –    2024-02-27 4 AS $20.11 $685,148 D/D (34,070) 240,253 -28%     
   Jaen Juan C. President   •       –      –    2024-02-27 4 AS $20.10 $464,953 I/I (23,132) 1,188,233 -28%     
   Jarrett Jennifer Chief Operating Officer   •       –      –    2024-02-26 4 AS $20.07 $492,819 D/D (24,555) 274,323 -26%     
   Jaen Juan C. President   •       –      –    2024-02-26 4 AS $20.06 $78,234 I/I (3,900) 1,211,365 -26%     
   Gilead Sciences Inc 10% Owner   –       –       •   2024-01-29 4 B $21.00 $319,999,995 D/D 15,238,095 30,061,124 2.45 -4%     
   Goeltz Ii Robert C. Chief Financial Officer   •       –      –    2024-01-23 4/A A $0.00 $0 D/D 22,000 73,831     -
   Jarrett Jennifer Chief Operating Officer   •       •      –    2024-01-23 4 A $0.00 $0 D/D 40,000 298,878     -
   Jaen Juan C. President   •       •      –    2024-01-23 4 A $0.00 $0 D/D 40,000 341,475     -
   Nuyten Dimitry Sa Chief Medical Officer   •       –      –    2024-01-23 4 A $0.00 $0 D/D 28,000 99,195     -
   Rosen Terry J Chief Executive Officer   •       •      –    2024-01-23 4 A $0.00 $0 D/D 100,000 3,966,974     -
   Tang Carolyn C. General Counsel   •       –      –    2024-01-23 4 A $0.00 $0 D/D 26,700 114,579     -
   Azoy Alexander Chief Accounting Officer   •       –      –    2024-01-23 4 A $0.00 $0 D/D 8,850 19,070     -
   Goeltz Ii Robert C. Chief Financial Officer   •       –      –    2024-01-23 4 A $0.00 $0 D/D 21,300 73,131     -
   Goeltz Ii Robert C. Chief Financial Officer   •       –      –    2024-01-02 4 AS $20.00 $40,080 D/D (2,004) 51,831 -26%     
   Jaen Juan C. President   •       •      –    2024-01-02 4 AS $20.09 $140,128 I/I (6,975) 1,215,265 -26%     
   Rosen Terry J Chief Executive Officer   •       •      –    2023-12-29 4 A $0.00 $0 D/D 448 3,866,974     -
   Jarrett Jennifer Chief Operating Officer   •       •      –    2023-12-22 4 AS $17.76 $382,213 D/D (21,521) 258,878 -20%     
   Azoy Alexander Chief Accounting Officer   •       –      –    2023-12-20 4 D $18.21 $1,238 D/D (68) 10,220     -
   Jaen Juan C. President   •       •      –    2023-12-19 4 D $18.09 $113,225 D/D (6,259) 301,475     -
   Azoy Alexander Chief Accounting Officer   •       –      –    2023-12-19 4 D $18.09 $11,957 D/D (661) 10,288     -
   Nuyten Dimitry Sa Chief Medical Officer   •       –      –    2023-12-19 4 D $18.09 $27,859 D/D (1,540) 71,195     -
   Tang Carolyn C. General Counsel   •       –      –    2023-12-19 4 D $18.09 $73,735 D/D (4,076) 87,879     -
   Goeltz Ii Robert C. Chief Financial Officer   •       –      –    2023-12-19 4 D $18.09 $50,797 D/D (2,808) 53,835     -
  88 Records found
  1  2  3  4   
  Page 1 of 4
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us